Form 4: ClearPoint Neuro Director B. Kristine Johnson Reports Stock Transactions
SEC Form 4 Filing
Director B. Kristine Johnson reports the conversion of restricted stock units into common stock and subsequent disposal of shares.
Summary
- On May 14, 2024, B. Kristine Johnson, a director of ClearPoint Neuro, Inc., reported a transaction involving the conversion of 17,153 restricted stock units into common stock.
- Following the conversion, the director disposed of 37,606 shares of common stock.
- After the reported transactions, the director still beneficially owns 0 shares.
- The restricted stock units were granted on May 25, 2023, and vested on the earlier of the first anniversary of the grant date or the day immediately preceding the company's 2024 annual meeting of stockholders.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- Shareholders are informed about the director's stock transactions, providing transparency into insider activity.
Key Dates
| Date | Description |
|---|---|
| May 25, 2023 | Reporting person was granted 17,153 restricted stock units. |
| May 14, 2024 | Restricted stock units converted into common stock and shares disposed of. |
| May 15, 2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.